<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616390</url>
  </required_header>
  <id_info>
    <org_study_id>L20220940</org_study_id>
    <nct_id>NCT05616390</nct_id>
  </id_info>
  <brief_title>Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Study to Evaluate the Efficacy and Safety of the Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Child-Pugh B and/or ECOG PS 2 Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver&#xD;
      protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular&#xD;
      carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2022</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the time from the date of treatment start to the date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 1 years</time_frame>
    <description>Defined as proportion of patients who have a best response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 1 years</time_frame>
    <description>Defined as proportion of patients who have a best response of CR, PR or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The improvement in quality of life as measured by the EORTC Quality of Life Questionnaire QLQ-C30 (V3.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg IV d1,Q3W</description>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5mg/kg IV d1,Q3W</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Liver Protective Support Therapy</intervention_name>
    <description>Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced unresectable hepatocellular carcinoma confirmed by histology or cytology&#xD;
&#xD;
          -  Age 20-79&#xD;
&#xD;
          -  At least one measurable lesion defined in RECIST version 1.1&#xD;
&#xD;
          -  Child Pugh grade B&#xD;
&#xD;
          -  ECOG PS score 2&#xD;
&#xD;
          -  The expected life is at least 90 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any&#xD;
             other treatment that regulates T cells&#xD;
&#xD;
          -  Received systemic corticosteroid or immunosuppressive therapy within 28 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Complicated with autoimmune diseases or having a history of chronic or recurrent&#xD;
             autoimmune diseases&#xD;
&#xD;
          -  History of pleural or pericardial adhesions within 28 days before enrollment&#xD;
&#xD;
          -  HIV antibody, HTV-â… antibody, HCV antibody, hepatitis B surface protein antigen,&#xD;
             hepatitis B surface protein antibody, hepatitis B core protein antibody or any&#xD;
             detectable hepatitis B virus DNA test results were positive&#xD;
&#xD;
          -  Multiple primary cancers (excluding completely resected basal cell carcinoma, stage I&#xD;
             squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial&#xD;
             bladder cancer, and any other cancer that has not recurred for at least 5 years)&#xD;
&#xD;
          -  Brain or meningeal metastasis (unless asymptomatic and does not require treatment)&#xD;
&#xD;
          -  Uncontrollable or serious cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huikai Li</last_name>
    <phone>862223340123</phone>
    <phone_ext>3091</phone_ext>
    <email>lihuikai@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huikai Li</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3091</phone_ext>
      <email>lihuikai@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>March 19, 2023</last_update_submitted>
  <last_update_submitted_qc>March 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sintilimab</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

